ScHARR is conducting a systematic review and network meta-analysis investigating biological treatment of rheumatoid arthritis not previously treated with disease-modifying anti-rheumatic drugs, and after the failure of conventional disease-modifying anti-rheumatic drugs only. This project is commissioned by the French National Authority for Health (HAS). It is an update of previous work by ScHARR, conducted for the National Institute for Health and Care Excellence, for the Technology Appraisal (TA375). The project, running in early 2017, compares seven biological disease-modifying anti-rheumatic drugs, as well as biosimilars.
